Chongqing University Team's Breakthrough in Pan-Cancer Vascular System Research
TapTechNews July 11th news, TapTechNews learned from the official WeChat public account of Chongqing University that the team of Professor Yin Mingzhu of the university published the latest research results in the international academic journal Nature at 23:00 Beijing time on the 10th. This research has for the first time constructed the largest holographic cell atlas of the pan-cancer vascular system, providing a panoramic perspective for fully understanding the complex process of tumor angiogenesis, and at the same time providing a scientific plan for clinically improving the efficacy of anti-angiogenesis therapy.
The occurrence and progression of tumors are closely related to the generation of blood vessels. Blood vessels are the basis for the survival and development of tumors by transporting nutrients to allow tumor cells to proliferate and metastasize. Comprehensively revealing the characteristics of the tumor vascular microenvironment and screening the key endothelial cells that supply energy to tumor cells can provide a strong basis for the precise treatment of clinical tumor patients through intervening in the supply of nutrients.
Therefore, in this research, the team of Professor Yin Mingzhu used single-cell transcriptome sequencing data of 31 kinds of human malignant tumors to deeply analyze the common and characteristic functional groups of vascular endothelial cells, lymphatic endothelial cells and perivascular cells in the pan-tumor microenvironment, and clearly explained the cell types and functional characteristics of the main components at each stage of tumor-induced angiogenesis. The research team pointed out that the appearance of tip cells at the initiation stage of tumor-induced vascular budding not only marks the disease progression of tumor patients, but is also closely related to the poor prognosis. The research found that the proportion of such cells can indicate the efficacy of anti-angiogenesis therapy. To sum up, such cells have great significance in the companion diagnosis of anti-angiogenesis therapy and are powerful biomarkers for indicating continuous therapeutic benefit in future clinical treatment. At the same time, the team is fully promoting the work of integration of industry, university and research according to the above research results, laying the foundation for the further clinical application of tumor efficacy evaluation for anti-angiogenesis therapy, and expecting to benefit more tumor patients in the future.